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The association between cyclin D1 over-expression with cancer prognosis and 
outcomes is controversial in different malignancies. In the presented meta-analysis we aim to 
comprehensively assess the relationship between tissue cyclin D1 expression levels and overall 
survival (OS) in diverse cancers. PubMed, EMBase, Scopus, Web of Sciences and Cochrane 
Library database were searched to explore eligible studies. For prognostic meta-analysis, study-
specific hazard ratios (HRs) of tissue cyclin D1 for survival were obtained. One hundred and 
fifteen studies with a total of 20,253 patients with 10 different cancer types were included in this 
meta-analysis. In pooled analysis, high expression of cyclin D1 was significantly associated with 
poor OS with a combined HR of 1.09 (95% CI: 1.01-1.19, P=0.034; random-effects). However, 
the sub-group analysis showed that elevated cyclin D1 expression was only associated with 
worse OS of head and neck cancers (HR=2.08, 95% CI: 1.75-2.47; P<0.001) but not in breast 
(HR=1.11, 95% CI: 0.93-1.32, P= 0.241), gastrointestinal (HR = 0.92, 95% CI:0.76-1.11; 
P=0.390), bladder (HR=0.94, CI: 0.84-1.04; P=0.225) and in lung cancer patients (HR=1.08, CI: 
0.80-1.45; P=0.613). Further large, prospective, and well-designed trials are warranted to 
determine the exact clinical significance of cyclin D1 over-expression for prognosis of cancer 
patients receiving treatment regimens. 





The transition from the different check-points of the cell cycle is controlled by cyclin-
dependent kinases (cdks), which are bound to their cyclin co-partners (1). Cyclin D1 (CycD1) as 
one of the D cyclins amplified in the G1 phase, coordinates the G1/S phase transition and DNA 
synthesis which in complex with cdk4 enhances phosphorylation of the retinoblastoma protein 
(pRb). Dephosphorylated Rb binds to transcription factors including that of the E2F family and 
inhibits their functions, whereas hyper-phosphorylated Rb dissociates from E2F, enhancing G1 
to S transition (2). CycD1 is composed of 295 amino acids and was initially isolated as the 
PRAD-1 putative oncogene. The CCND1 gene, encoding human cyclin D, is located at 
chr.11q13 and is frequently deregulated through chromosomal rearrangements, inversion, 
translocation, and over-expression.  
There are several studies showing that amplification of the CCND1 gene and/or CycD1 
over-expression is closely associated with outcome of patients with multiple types of malignant 
tumors (3). Consistent amplification of CCND1 affects the regulation of CycD1, leading to cell 
cycle disruption, growth promotion and carcinogenesis CCND1 amplification has been found in 
numerous human tumor types, and it is a key determinant of the behavior of malignancies, such 
as aggressiveness and high proliferative activity of the tumor (4). CyclinD1 gene is amplified in 
nearly 22-58% of several human malignancies and is closely related to overall survival in cancer 
patients, supporting the prognostic value of CycD1 in cancer patients (5, 6). However, the 
published findings are somehow controversial which could be due to relatively small study 
populations, low statistical power, and clinic-pathological heterogeneity. Thus, we conducted a 
meta-analysis to quantify prognostic value of CycD1 over-expression in patients with various 






Materials and Methods 
To find all related articles investigating the prognostic value of CycD1 over-expression in 
human cancers, we conducted a computerized literature search of PubMed, EMBase, Scopus, 
Web of Sciences and Cochrane Library database using the terms (Cyclin D1 OR Cyclin D) AND 
(prognosis OR prognostic OR outcome OR mortality OR survival) AND (cancer OR tumor OR 
malignancy OR neoplasm). The search was limited to human studies published in English. 
Reference lists of potential studies were also checked again to make sure that no relevant 
publications are missed. A flow diagram of the literature research is presented in Figure 1. 
 
Inclusion and exclusion criteria 
Studies were identified eligible if they met the following criteria: (1) they studied the 
patients with different solid tumors; (2) they measured the expression of CycD1 in tissue 
samples; (3) they explored the association between CycD1 expression levels and cancer 
survival. In vitro studies, duplicated or unqualified data, reviews, letters, conference abstracts, 
case reports or articles which do not provide sufficient information to calculate the HR about 
overall survival were excluded. 
  
Data extraction 
Data were carefully assessed and extracted independently from the eligible articles by 
two investigators (M.M.B. and A.B.). The following data were gathered: first author’s name, 
publication year, country, cancer type, sample type, stage, sample size, follow ups and hazard 
ratios (HRs) of CycD1 for overall survival (OS) with their 95% confidence intervals (CIs) and P 
value. When disagreement occurred between the two researchers, corresponding author 






Heterogeneity was assessed using Q statistics and Higgins I2 statistic (I2 > 50% or P < 
0.05 was considered heterogeneous) (7). If heterogeneity among the studies was not 
significant, fixed-effects model was applied. Otherwise, significant heterogeneity was resolved 
by using the random-effects model (8). The effect of CycD1 expression on OS was estimated by 
forest plots. Sub-group analysis of pooled HRs of cancer patients with high CycD1 expression 
was investigated with regard to the cancer type. In pooled HR, association between CycD1 
over-expression with prognosis was considered statistically significant if the 95% CI did not 
encompass 1. Publication bias was assessed through the symmetry of a funnel plot and Egger’s 
test, P>0.05 was considered representative of no publication bias (9). All analyses were 
conducted using the comprehensive meta-analysis software version 2 (Biostat, Inc., Englewood, 
NJ) (10).  
 
Results 
Study descriptions  
An initial search retrieved 565 potentially relevant publications, and after checking 
eligibility and exerting inclusion and exclusion criteria, a total of 115 qualified articles remained 
for the final analysis. These eligible articles were published between 1995 to 2017.  The 
minimum and maximum numbers of patients in these studies were 40 and 1785, respectively. 
  
Study characteristics 
One hundred and fifteen publications involving 20,253 subjects with different types of 
solid tumors were analyzed. The baseline characteristics of all studied populations are 
presented in Table 1. By cancer type, 10 different tumors including 7 oral cancer (OC), 4 head 
and neck squamous cell carcinoma (HNSCC), 11 esophageal cancer (EC), 24 lung cancer (LC), 
34 breast cancer (BC), 22 (CRC), 10 bladder cancer (BlC), 1 hepatocellular carcinoma (HCC), 1 
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gastric cancer (GC) and 1 melanoma were studied. Regionally, study groups were conducted in 
20 different countries including Switzerland (n=3), Italy (n=6), Korea (n=6), Greece (n=4), Spain 
(n=5), USA (n=12), Japan (n=21), China/Taiwan (n=2), Germany (n=5), China (n=11), Austria 
(n=3), Poland (n=4), Canada (n=1), Sweden (n=4), Netherlands (n=2), Norway (n=3), Finland 
(n=2), France (n=1), Taiwan (n=3), and Egypt (n=1). By detection method, various techniques 
were used including 104 immunohistochemistry (IHC), 6 fluorescence in situ hybridization 
(FISH), 6 PCR, 1 western blotting (WB), 1 chromogenic in situ hybridization (CISH), 1 slot blot 
hybridization (SBH), and 1 microarray. Based on sample size, studies were conducted in <100 
patients (n=40), 100-200 patients (n=50), and >200 (n=25). 
 
Overall association 
In the pooled analysis, high expression of CycD1 was significantly associated with poor 
OS with a combined HR of 1.09 (95% CI: 1.01-1.19, P=0.034; Figure 2). The random-effects 
model was used due to the high heterogeneity [I2 = 75.2%; Q = 471.8; degrees of freedom (df) = 
117; P<0.001] in the pooled analysis,  
 
Sub-group analysis 
Because of the significant heterogeneity between the association of CycD1 expression 
level and OS of cancer patients, we conducted sub-group meta-analysis to explore whether the 
heterogeneity is due to different cancer types or population size. In the stratified analysis by 
cancer types (Figure 3), CycD1 over-expression was associated with worse OS of head and 
neck cancers (11 studies; HR=2.08, 95% CI: 1.75-2.47; P<0.001; random effect model). 
However, CycD1 over-expression was not significantly associated with OS among breast 
cancer patients (34 studies; HR=1.11, 95% CI:0.93-1.32, P= 0.241; random  effect), 
gastrointestinal cancer patients (35 studies; HR = 0.92, 95% CI:0.76-1.11; P=0.390; random 
effect), bladder cancer patients (10 studies; HR=0.94, 95%CI:0.84-1.04; P=0.225; random 
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effect) and lung cancer patients (24 studies; HR=1.08, 95% CI:0.80-1.45; P=0.613; random  
effect). The result of Egger’s test indicated no publication bias among studies (Figure 4). 
 
Discussion 
The CCND1/pRb pathway is one of the crucial pathways regulating the cell cycle in 
human tumors. Over-expression of CycD1 contracts the G1 phase, reduces cell size, and 
decreases cellular dependency on mitogens in vitro and in vivo (11). CycD1 expression is 
altered in human malignancies, suggesting that its deregulation is implicated in tumorgenesis. 
The presence of both contradicting findings addressing the significance of CycD1 over-
expression in different cancers made it necessary to conduct a quantitative assessment of the 
survival results. Our findings indicated that patients with CycD1-positive tumors had a lower 
survival rate compared to those with CycD1 negative tumors. The sub-group analysis suggested 
that elevated cyclin D1 expression was significantly associated with worse OS of head and neck 
cancers. However, CycD1 over-expression was not significantly associated with OS among 
patients with BC, LC, Blc and gastrointestinal cancers.   
Consistent with our findings, it has been shown that the CycD1 gene is amplified in 12% 
to 68% and protein overexpressed in up to 80% of all HNSCC cases. Importantly, in a large 
number of tumors, over-expression of CycD1 does not reveal DNA amplification. It is believed 
that protein expression of CycD1 is more directly affected by increased CycD1 mRNA level than 
CycD1 gene amplification. Similarly, in a transgenic mice model, increased expression of CycD1 
induces formation and development of dysplasic lesions in the oral cavity and esophagus 
region, suggesting that CycD1 over-expression could be associated with local invasiveness and 
a relatively aggressive behavior of head and neck tumors (12). Moreover, Nakashima et al. 
demonstrated that administration of  anti-sense CycD1 cDNA suppresses cell growth and 
invasiveness of head and neck tumors in in vivo and in vitro models (13). Furthermore, it has 
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been shown that anti-tumor activities of flavopiridol are at least partially mediated by down-
regulation of CycD1 in head and neck squamous cell carcinoma (14). 
The significance of CycD1 in the head and neck tumors supports the therapeutic 
potency of CDK inhibitors in this cancer group. In line with this, several clinical trials have been 
completed or ongoing using cdks inhibitors in different advanced cancer patients 
(NCT00141297, NCT00147485, NCT00020189, and etc).  
This meta-analysis has several limitations. First, only English language published 
studies were enrolled in our study. Second, our findings were based on study-level and not on 
individual case information. Individual case information could indicate more reliable estimates of 
the association. Third, in this meta-analysis, a random-effects model was predominantly used 
due to their significant heterogeneity. Variations in countries, tumor types, disease stages, 
therapeutic strategy, the cutoff values for CycD1 over-expression, small population size or 
mixed cancer analysis, variations in methodology and other variables might involve relatively 
high heterogeneity in the present study. Although IHC was the most frequently used method for 
detecting cyclin D1 in situ, other methods including RT-qPCR, FISH, PCR, WB, CISH, SBH, and 
microarray have also been used for the quantification of the levels of CycD1 mRNA expression 
in tumor tissue sections. 
In conclusion, despite the limitations mentioned above, our meta-analysis demonstrates 
that the over-expression of CycD1 is associated with a poor prognosis in head and neck cancer 
patients and could be a potential prognostic indicator for this cancer type. However, several 
issues should be well resolved before using CycD1 as diagnostic and prognostic indicators in 
the clinical setting. Acquisition of specimens from non-invasive circulating biomarkers (plasma, 
serum or other body fluid) is more convenient than tissue samples. Moreover, the prognostic 
value of CycD1 in cancer patients should be assessed in the context of other related molecular 
biomarkers. For instance, compared to CycD1 alone, co-expression of CycD1, p21, EGFR, Bcl-
2, PCNA and p53 could be a more reliable independent prognostic marker for predicting survival 
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(15). Well-designed investigations focused on specific cancer types and large target population 
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Figure legends:  
Figure1. Flowchart of search strategy and selection process  
Figure 2. Forest plot investigating the association between cyclin D1 expression and overall 
survival in all patients with different solid tumors 
Figure 3. Forest plot studying the association between cyclin D1 expression and overall survival 
in patients with A) gastrointestinal cancer, B) breast cancer, C) head and neck cancers, D) 
bladder cancer, and E) lung cancer. 
Figure 4. Funnel plot showing the association between cyclin D1 expression and overall 









Table 1. Characteristics of eligible studies 
Study 
number 





Overall Survival Technique Sample 
Bladder 
(16) 2014 Switzerland 152 cN0cM0 86.4 1.37(0.8-2.32) FISH 
IHC 
FFPE 
(17) 2006 Italy 82 Muscle-
invasive 
21 0.73(0.37-1.45) IHC FFPE 
(18) 2010 Korea 103 0-IV 31.5 1.98 (0.92-4.23) IHC FFPE 
(19) 2010 Greece 157 Muscle-
invasive 
44.95 0.95(0.91-0.99) IHC FFPE 
(20) 2004 Spain 159 Superficial 74.8 1.87(0.78-4.44) IHC FFPE 
(21) 2002 Italy 96 Superficial 50 0.39(0.14-1.12) IHC FFPE 
(22) 2007 USA 74 Superficial 42.3 0.62(0.26-1.47) IHC FFPE 
(23) 2000 Japan 102 I-IV 41 0.46(0.21-0.99) IHC FFPE 
(6) 2001 UK 150 I-IV 35 0.42(0.22-0.80) IHC FFPE 
(24) 2006 Spain 84 I-IV 36.4 0.96(0.92-1.01) IHC Frozen 
tissue 
Oral 
(4) 2012 China/ 
Taiwan 
264 I-IV 46.5 1.70(1.17-2.48) IHC FFPE 
(25) 2002 Japan 41 I-IV 36.3 1.87(0.14-24.24) IHC FFPE 
(26) 1999 China/ 
Taiwan 
88 I-IV >60 2.06(1.48-2.62) IHC FFPE 
(27) 2000 Japan 94 I-IV >60 3.03(1.09-8.47) IHC FFPE 
(28) 2009 India 135 I-IV >24 1.28(0.65-2.52) IHC FFPE 
(29) 2005 Japan 140 I-IV 66 1.68(0.84-3.34) IHC FFPE 
(30) 2003 India 84 I-IV 60 2.04(1.09-3.83) IHC FFPE 
Esophageal cancer 
(31) 1998 Japan 77 I-IV 60 2.44(1.16-5.12) IHC FFPE 
(32) 2006 Japan 119 I-IV 60 2.07(1.12-3.83) IHC FFPE 
(33) 2003 Germany 63 I-IV 48 2.70(1.279-5.714) IHC FFPE 
(34) 2001 Japan 416 I-IV 24 1.42(1.04-1.94) IHC FFPE 
(35) 1999 Japan 88 0-IV 60 2.47(1.01-6.06) IHC Tissue 
(36) 2001 Japan 86 0-IV <60 0.40(0.17-0.93) IHC FFPE 
(37) 1999 Germany 172 I-IV 19 2.14(1.34-3.42) IHC FFPE 
(38) 2002 Japan 144 0-IV <80 0.69(0.39-1.23) IHC FFPE 
(39) 2014 China 82 I-IV 1-39 2.11(1.029-4.347) IHC FFPE 
(40) 2012 China 100 I-IV NR 2.259(1.15-4.439) IHC Frozen 
tissue 
(41) 2005 USA 63 I-IV 35 0.3(0.12-0.71) IHC FFPE 
Lung 
(42) 2000 USA 130 I-IV 76 0.53(0.29-0.98) IHC FFPE 
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(43) 2010 China 115 I-IV 22 1.59(1.04-2.43) IHC FFPE 
(44) 2010 Austria 390 I-IV 39.6 1.58(1.09-2.28) IHC FFPE 
(45) 2010 Italy 87 IIIA pN2 140.4 0.22(0.12-0.42) IHC FFPE 
(46) 2009 USA 147 I-IV 39.4 0.56(0.35-0.88) IHC FFPE 
(47) 2009 Poland 166 I-IV 60 0.82(0.26-1.38) IHC FFPE 
(48) 2008 Spain 67 I 3-120 4.05(1.46-11.25) IHC FFPE 
(49) 2008 China 102 I-IV 23.5 2.79(1.47-5.28) IHC FFPE 
(50) 2008 USA 69 I-IV 27.3 1.14(0.34-3.84) RT-PCR FFPE 
(51) 2005 Austria 105 I-III 25 1.75(1.25-2.45) IHC FFPE 
(52) 2005 Poland 111 I-IV 62 1.02(0.44-1.59) IHC FFPE 
(53) 2004 China 43 I-IV 4-95 0.42(0.06-2.80) IHC FFPE 
(54) 2004 USA 63 I-III 44 0.97(0.44-2.20) IHC FFPE 
(55) 2004 Canada 284 NA 31.2 0.39(0.20-0.76) IHC FFPE 
(56) 2003 UK 48 I-IV 18 0.13(0.03-0.62) IHC FFPE 
(57) 2003 China 55 I-IV 4-80 1.57(1.02-2.46) IHC FFPE 
(58) 2001 Japan 106 I-II >18 3.93(1.68-9.22) IHC FFPE 
(59) 2001 Japan 104 p-stage I 6-132 1.25(0.61-2.58) IHC FFPE 
(60) 2000 1Czech 88 I-IV 24-36 2.21(1.30-3.75) IHC FFPE 
(61) 1999 Japan 111 I-IV 6-84 0.16(0.02-1.22) IHC FFPE 
(62) 1999 Korea 69 I-IIIA 0.5-108 2.13(1.28-3.56) IHC FFPE 
(63) 1997 Japan 208 I-IIIB <84 0.63(0.42-0.95) IHC FFPE 
(64) 1999 Japan 51 I-IIIA 52.5 1.05(0.42-2.61) IHC FFPE 








Greece 364 NR 75 0.54(0.32-0.91) IHC FFPE 
ER+ 242 3.1(1.3-7.1) 
115 0.3(0.1-2.4) 
ER- 
(67) 2017 Sweden 357 T1-2N0M0  0.94(0.63-1.4) IHC 
FISH 
FFPE 
(3) 2017 Spain 179 I-IV <120 0.12(0.035-0.44) IHC FFPE 
(68) 1996 Italy 180 II-III 72 0.67(0.39-1.14) IHC FFPE 
(69) 1996 Netherland 248 I-II 106 1.03(0.7-1.52) IHC FFPE 
(70) 2007 China 140 I-III 60 2.05(1.08-3.89) IHC FFPE 
(71) 2001 Norway 170 NR 58.8 0.76(0.33-1.78) IHC FFPE 
(72) 2007 Korea 333 I-III 57 0.83(0.54-1.29) IHC FFPE 
(73) 2003 Korea 128 I-III 1-116 0.31(0.14-0.69) IHC FFPE 
(74) 1995 UK 93 NR NR 1.1(0.3-4.05) IHC FFPE 
(75) 2009 USA 150 NR 75 2.38(1.25-4.52) IHC Tissue 
(76) 1997 USA 148 I-II 83 0.76(0.43-1.34) IHC FFPE 
(77) 2000 USA 123 NR 48 1.72(1.01-2.94) IHC Tissue 
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(1) 1999 UK 253 I-II 75 1.22(0.70-2.11) NB FFPE 
(80) 2000 Japan 97 NR 40.8 0.43(0.16-1.19) PCR Frozen 
tissues 
(81) 2008 Spain 129 I-III 50 2.89(0.92-9.04) PCR Plasma 
(82) 2013 Finland 102 I-IV <120 3.93(1.23-12.6) IHC FFPE 
(83) 
 
2008 Austria 253 NR NR 2.47(1.08-5.03) IHC Tissue 
)84( 2010 Germany 661 I-II NR 1.38(0.87-2.2) Microarray Tissue 
(85) 2012 Germany 100 NR 120 1.06(0.89-1.28) IHC FFPE 
(86) 2003 Switzerland 187 III 66 0.91(0.58-1.43) IHC FFPE 
(87) 2012 China 199 II-III 60 2.50(1.20-6.40) IHC FFPE 
(88) 2003 Korea 175 I-III >60 0.79(0.32-1.94) IHC FFPE 
(89) 
ER+ 
2009 UK 301 I-IV 87 2.57(1.04-6.35) IHC FFPE 
(90) 2006 Norway 82 NR 120 0.34(0.10-1.00) RT-PCR 
IHC 
FFPE 
(91) 2004 France 296 NR 84 1.60(0.70-3.60) SB Tissue 
(92) 2004 Switzerland 1785 I-IV 68 1.26(1.01-1.57) FISH FFPE 
(93) 1996 Australia 1014 I-III 66 1.00(0.60-1.50) SBH Tissue 
(94) 2006 UK 206 I-III 67 1.60(0.57-4.49) IHC 
CISH 
FFPE 
(95) 2008 UK 115 I-III 77.4 1.80(1.05-3.07) FISH Tissue 
(96) 2010 Italy 53 IIIB 125 0.75(0.26-2.12) FISH FFPE 




(98) 2011 USA 100 III-IV 107 3.64(2.2-6.03) IHC FFPE 
(99) 1997 Japan 45 I-IV 44.5 1.16(0.37-3.59) PCR 
IHC 
FFPE 
(100) 1996 Sweden 75 I-IV 18 3(1.2-7.4) IHC FFPE 
(101) 1999 Australia 147 I-IV 57 3.89(1.37-11.07) IHC FFPE 
HCC  





(103) 2011 Japan 78 I-IV 40 1.10(0.29-4.13) IHC FFPE 
GC 








(105) 2001 UK 126 A-D* 28.56 0.24(0.07-0.81) IHC FFPE 
(106) 2004 Egypt  60 I-IV 30 10.87(1.05-86.25) IHC FFPE 
(107) 2005 Poland  111 A-D* NR 0.74(0.33-1.68) IHC FFPE 
(108) 2012 Netherland 386 II-III NR 0.68(0.45-1.02) IHC FFPE 
(109) 2001 India 98 B , C * 60 0.96(0.41-2.27) IHC FFPE 
(110) 2004 Norway 219 A-D* 60 1.10(0.47-2.57) IHC FFPE 
(111) 2009 China 620 I-IV 52 0.60(0.41-0.88) IHC FFPE 
(112) 2005 Finland 363 A-D* NR 1.09(0.67-1.78) IHC FFPE 
(113) 2012 Korea 217 I-IV NR 0.63(0.36-1.09) IHC FFPE 
(114) 2006 UK 90 C* 60-100 0.84(0.37-1.95) IHC FFPE 
(115) 1997 Japan 101 NR 60 0.73(0.22-2.38) IHC FFPE 
(116) 2010 China 169 I-IV 92.1 0.47(0.25-0.87) IHC FFPE 
(117) 2002 UK 249 A-D* 35 1.17(0.70-1.93) IHC FFPE 
(118) 2004 USA 40 T3–4 or N1 69 0.83(0.13-5.30) IHC FFPE 
(119) 2009 USA 602 I-IV every 2 
Years 
0.67(0.48-0.92) IHC FFPE 
(120) 1998 Sweden 90 A-C* 42 0.34(0.10-1.23) IHC FFPE 
(121) 2001 Poland 122 I-IV 44.5 1.29(0.63-2.66) IHC FFPE 
(122) 2007 Greece 86 A-D* 43 0.77(0.30-2.00) IHC FFPE 
(123) 2013 Taiwan 100 I-III 30.5 0.37(0.16-0.84) IHC FFPE 
(124) 2008 Germany 200 I-IV >60 1.18(0.67-2.10) IHC FFPE 
(125) 2013 China 139 I-IV NR 0.41(0.19-0.90) IHC FFPE 
(126) 2010 Greece 144 I-IV NR 0.51(0.21-1.22) IHC FFPE 
NR=Not reported, FISH=Fluorescence In situ Hybridization, WB=western blotting, CISH= Chromogenic In Situ Hybridization, 
HNSCC= Head and Neck Squamous Cell Carcinoma, HCC= hepatocellular carcinoma, GC= gastric cancer, ESCC = 
esophageal squamous cell carcinoma  
SBH= Slot blot hybridization. PCR=Polymerase Chain Reaction, FFPE= formalin-fixed paraffin embedded, 
IHC=Immunohistochemistry. 
 
